Cite
MLA Citation
Hagop M. Kantarjian et al.. “Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study.” Cancer, vol. 125, no. 14, 2019, pp. 2474–2487. http://access.bl.uk/ark:/81055/vdc_100086830350.0x00005b